

## AMENDMENTS TO THE SPECIFICATION

Kindly amend the specification to insert sequence identifiers as follows.

Page 3, lines 6-26:

WO99/07404 discloses Exendin agonists having a general formula I that defines a peptide sequence of 39 amino acid residues with Gly Thr in positions 4-5, Ser Lys Gln in positions 11-13, Glu Glu Glu Ala Val Arg Leu (SEQ ID NO: 101) in positions 15-21, Leu Lys Asn Gly Gly (SEQ ID NO: 102) in positions 26-30, Ser Ser Gly Ala (SEQ ID NO: 103) in positions 32-35, and wherein the remaining positions may be occupied by wild-type Exendin amino acid residues or may be occupied by specified amino acid substitutions. The formula I does not cover any Exendin agonists or analogues having specific amino acid deletions and/or being conjugates as described herein, such as the novel compounds desPro<sup>36</sup>-Exendin-4(1-39) (SEQ ID NO: 104), Exendin-4(1-39)-K<sub>6</sub> (SEQ ID NO: 105) or desPro<sup>36</sup>-Exendin-4(1-39)-K<sub>6</sub> (SEQ ID NO: 1).

WO 99/25727 discloses Exendin agonists having a general formula I that defines a peptide sequence of from 28 to 38 amino acid residues with Gly in position 4 and Ala in position 18, and wherein the remaining positions may be occupied by wild-type Exendin amino acid residues or may be occupied by specified amino acid substitutions. Formula I does not comprise a peptide sequence having Ser as the C-terminal amino acid and Exendin agonists or analogues having specific amino acid deletions and/or being conjugates as described herein, such as the novel compounds desPro<sup>36</sup>-Exendin-4(1-39) (SEQ ID NO: 104), Exendin-4(1-39)-K<sub>6</sub> (SEQ ID NO: 105) or desPro<sup>36</sup>-Exendin-4(1-39)-K<sub>6</sub> (SEQ ID NO: 1). Further, formula II of WO 99/25727 defines a peptide sequence similar to formula I, but including Exendin derivatives having a C(1-10)alkanoyl or cycloalkylalkanoyl substituent on lysine in position 27 or 28.

Page 10, lines 32-35:

Figure 9 shows the sequences of Compound 1 (des Pro<sup>36</sup> Exendin-4 (1-39)-K<sub>6</sub>) and stabilized compounds of Compound 1 (SEQ ID NO: 1), namely Compound 2 (SEQ ID NO: 2), 3 (SEQ ID NO: 3), 4 (SEQ ID NO: 4), 5 (SEQ ID NO: 5), 6 (SEQ ID NO: 6), 7 (SEQ ID NO: 7), 11 (SEQ ID NO: 11), 12 (SEQ ID NO: 12), 13 (SEQ ID NO: 13), and 14 (SEQ ID NO: 14) as well as stabilized compounds of Exendin-4 (1-39), namely Compounds 8 (SEQ ID NO: 8), 9 (SEQ ID NO: 9), and 10 (SEQ ID NO: 10).

Page 12, lines 6-24:

In embodiments in which the stabilized Exendin-4 compound or related composition includes at least one Z peptide and preferably one or two of same, Z comprises at least one Lys amino acid unit, typically between about 4 to about 20 Lys amino acid units, preferably about 6 Lys (SEQ ID NO: 106) amino acid units.

More particular stabilized Exendin-4 (1-39) compounds according to the invention are represented by the following sequences:

des Pro<sup>36</sup> [Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 15),  
des Pro<sup>36</sup> [IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 16),  
des Pro<sup>36</sup> [Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 17),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup>]Exendin-4 (1-39) (SEQ ID NO: 18),  
des Pro<sup>36</sup> [Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 19),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 20),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 21),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 22),

des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 23),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup> Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 24),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup> Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 25),  
des Pro<sup>36</sup> [Met(O)<sup>14</sup> Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 26), or  
a pharmaceutically acceptable salt or solvate thereof.

Page 12, lines 25-28:

In one embodiment of the forgoing compounds, each sequence is attached at the N- or C-terminus to the following group: -Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 106). Preferably, the group is attached to the C-terminus of the sequence.

Page 13, line 1-page 15, line 5:

Additionally specific stabilized Exendin-4 (1-39) compounds include the following sequences:

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup> [Asp<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 27)  
des Asp<sup>28</sup> Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup>Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 28),  
H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 29)  
H-Asn-(Glu)<sub>5</sub> des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 30),  
des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 31),  
H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 32),  
H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 33),  
  
H-(Lys)<sub>6</sub>- des Pro<sup>36</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 34),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39)-NH<sub>2</sub> (SEQ ID NO: 35),  
H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 36)  
H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39)-NH<sub>2</sub> (SEQ ID NO: 37),  
des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 38),  
H-(Lys)<sub>6</sub> des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 39),  
H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 40),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 41),  
H- des Asp<sup>28</sup> Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 42),  
H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 43),  
H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 44),  
des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 45),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 46),  
H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 47),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 48),  
des Cyclic imide<sup>28</sup> Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4(1-39)-NH<sub>2</sub> (SEQ ID NO: 49),  
H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ

ID NO: 50),

H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-NH<sub>2</sub>  
(SEQ ID NO: 51),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 52),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub>  
(SEQ ID NO: 53),

H-Asn-(Glu)<sub>5</sub>-des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 54),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 55),

des Met(O)<sup>14</sup> Asp<sup>28</sup> Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 56),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 57),

H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>] Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO: 58),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 59),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 60),

H-Asn-(Glu)<sub>5</sub> des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 61),

H-Lys<sub>6</sub>- des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 62),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-NH<sub>2</sub> (SEQ ID NO: 63),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ

ID NO: 64),

H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-NH<sub>2</sub>  
(SEQ ID NO: 65),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID  
NO: 66),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub>  
(SEQ ID NO: 67),

H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-  
NH<sub>2</sub> (SEQ ID NO: 68),

H-Lys<sub>6</sub>- des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO:  
69),

H- des Asp<sup>28</sup> Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ ID NO:  
70),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub> (SEQ  
ID NO: 71),

H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39) -NH<sub>2</sub>  
(SEQ ID NO: 72),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID  
NO: 73),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub>  
(SEQ ID NO: 74),

H-Asn-(Glu)<sub>5</sub>-des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-  
NH<sub>2</sub> (SEQ ID NO: 75),

H-Lys<sub>6</sub>- des Pro<sup>36</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-Lys<sub>6</sub>-NH<sub>2</sub> (SEQ

ID NO: 76),

des Cyclic imide<sup>28</sup> Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>] Exendin-4(1-39)-NH<sub>2</sub> (SEQ ID NO: 77),

H-(Lys)<sub>6</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39) - NH<sub>2</sub> (SEQ ID NO: 78),

H-Asn-(Glu)<sub>5</sub>- des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-NH<sub>2</sub> (SEQ ID NO: 79),

des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 80),

H-(Lys)<sub>6</sub>-des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 81),

H-Asn-(Glu)<sub>5</sub>-des Pro<sup>36</sup>, Pro<sup>37</sup>, Pro<sup>38</sup> [Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4(1-39)-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 82),

or a pharmaceutically acceptable salt or solvate thereof.

Page 15, line 23- page 16, line 8:

Also envisioned are pharmaceutically acceptable salts or solvates of such compounds. Examples of such stabilized Exendin-4(1-39) compounds include the following sequences:

[Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 83),

[IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 84),

[Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 85),

[Met(O)<sup>14</sup>]Exendin-4 (1-39) (SEQ ID NO: 86),

[Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 87),

[Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 88),

[Met(O)<sup>14</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 89),

[Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 90),

[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 91),  
[Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 92),  
[Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 93),  
[Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 94),  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 95)  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 96), or  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 97).  
and a pharmaceutically acceptable salt or solvate thereof.

Page 20, line 7-page 21, line 14:

In one embodiment, the pharmaceutically acceptable compositions disclosed herein can include at least one of the following sequences:

des Pro<sup>36</sup>[Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 15),  
des Pro<sup>36</sup>[IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 16),  
des Pro<sup>36</sup>[Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 17),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>]Exendin-4 (1-39) (SEQ ID NO: 18),  
des Pro<sup>36</sup>[Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 19),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 20),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 21),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 22),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 23),  
des Pro<sup>36</sup>[Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 98),  
des Pro<sup>36</sup>[Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 99),  
des Pro<sup>36</sup>[Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 100),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 23),  
des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 24),



des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 25), and des Pro<sup>36</sup>[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 26), or a pharmaceutically acceptable salt or solvate thereof.

Each of the specified compounds may optionally include the following group linked to the N- or C-terminus thereof, preferably the C-terminus: -Lys<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 106).

Additionally specific pharmaceutically acceptable compositions according to the invention include at least one of the following compounds:

[Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 83),  
[IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 84),  
[Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 85),  
[Met(O)<sup>14</sup>]Exendin-4 (1-39) (SEQ ID NO: 86),  
[Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 87),  
[Met(O)<sup>14</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 88),  
[Met(O)<sup>14</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 89),  
[Met(O)<sup>14</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 90),  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>]Exendin-4 (1-39) (SEQ ID NO: 91),  
[Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 92),  
[Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 93),  
[Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 94),  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Asp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 95),  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, IsoAsp<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 96); and  
[Met(O)<sup>14</sup>, Trp(O<sub>2</sub>)<sup>25</sup>, Cyclic imide<sup>28</sup>]Exendin-4 (1-39) (SEQ ID NO: 97)

or a pharmaceutically acceptable salt or solvate thereof.

Page 31, lines 22-24:

Compound 1 (des Pro<sup>36</sup> Exendin-4 (1-39)-K<sub>6</sub>) (SEQ ID NO: 1) has the structure shown in Figure 1 and it was made using the Merrifield technique. See the PCT/DK00/00393 application, for example, for more information.

Page 33, lines 5-8:

Peptide synthesis of Compound 8, H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Glu-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH<sub>2</sub> (SEQ ID NO: 8) ([Glu<sup>13</sup>]Exendin-4-NH<sub>2</sub> (SEQ ID NO: 8) on TentaGel S-RAM.

Page 33, lines 24-27:

Peptide synthesis of Compound 9, H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Glu-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asp-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH<sub>2</sub> (SEQ ID NO: 9) ([Glu<sup>13</sup>, Asp<sup>28</sup>]Exendin-4-NH<sub>2</sub> (SEQ ID NO: 9)) on TentaGel S-RAM.

Page 34, lines 10-13:

Peptide synthesis of Compound 10, H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asp-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH<sub>2</sub> (SEQ ID NO: 10) ([Asp<sup>28</sup>]Exendin-4-NH<sub>2</sub> (SEQ ID NO: 10)) on TentaGel S-RAM.

Page 34, lines 29-32:

Peptide synthesis of **Compound 11**, H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Glu-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH<sub>2</sub> (SEQ ID NO: 11) (des Pro<sup>36</sup>-[Glu<sup>13</sup>]Exendin-4-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 11)) on TentaGel S-RAM.

Page 35, lines 16-19:

Peptide synthesis of **Compound 12**, H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met(O)-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH<sub>2</sub> (SEQ ID NO: 12) (des Pro<sup>36</sup>-[Met(O)<sup>14</sup>]Exendin-4-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 12)) on TentaGel S-RAM.

Page 36, lines 4-7:

Peptide synthesis of **Compound 13**, H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met(O<sub>2</sub>)-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH<sub>2</sub> (SEQ ID NO: 13). (des Pro<sup>36</sup>-[Met(O<sub>2</sub>)<sup>14</sup>]Exendin-4-(Lys)<sub>6</sub>-NH<sub>2</sub> (SEQ ID NO: 13)) on TentaGel S-RAM.

Kindly insert the sequence listing filed herewith at the end of the specification.